key: cord-1050831-aslpshdb
authors: Khatri, Prabin; Agrawal, Krishna Kumar; Sharma, Dipesh; Chhetri, Pradip; Neupane, Aryan; Piriyani, Rano Mal; Baral, Pawan Puspa; Sapkota, Suman Raj; Banjade, Ashish; Chhetri, Ashmita; Bhandari, Subarna; Bharali, Swaraj
title: Prevalence of Elevated D-dimer Levels in Confirmed COVID-19 Cases in Intensive Care Unit of a Tertiary Care Centre of Western Nepal
date: 2021-03-31
journal: JNMA J Nepal Med Assoc
DOI: 10.31729/jnma.6284
sha: f79b83391c09520f75e3318b5e4ad6a9eb1923c9
doc_id: 1050831
cord_uid: aslpshdb

INTRODUCTION: D-dimer is currently the best available marker for COVID-19 associated hemostatic abnormalities. This study aims to find out the prevelance of elevated D-dimer levels in confirmed COVID-19 cases in intensive care unit of a tertiary care hospital of western Nepal. METHODS: This descriptive cross-sectional study was conducted among 95 patients admitted to COVID Intensive Care Unit of a teriary care centre from August 2020 to January 2021 after taking ethical clearence from Institutional Review Committee in order to determine the D-dimer levels in confirmed COVID-19 cases. D-dimer value was measured at the admission and the highest D-dimer value was recorded during the course of hospital stay with the risk of mortality in confirmed COVID-19 cases. The normal range of D-dimer was taken as <0.35 mg/dl as per our hospital laboratory standards. Convenience sampling method was used. Data entry and descriptive analysis were done in Statistical Package for the Social Sciences version 25.0, point estimate at 95% Confidence Interval was calculated along with frequency and proportion for binary data. RESULTS: Out of total 95 cases of COVID-19 included in this study, 25 (89.3%) patients with age ≥65 years and 42 (62.69%) patients aged <65 years had elevated D-dimer on admission. Data showed that 29 (67.4%) patients having elevated D-dimer at admission had mortality. CONCLUSIONS: Elevated D-dimer levels was frequently seen in patients admitted in Intensive Care Unit with COVID-19. Our study suggested that measurement of D-dimer may guide in clinical decision making.

COVID-19 triggers coagulation cascade, which is linked with a hypercoagulable state and worse clinical outcomes. 1, 2 Presence of thrombi within the pulmonary vasculature is associated with diffuse alveolar damage seen in most patients who died from COVID-19. 2, 3 Hemostasis based laboratory monitoring and treatment seems crucial owing to dysfunctional coagulation in COVID-19. 4 D-dimer is currently the best available marker for COVID-19 associated hemostatic abnormalities. 5 The determination of circulating D-dimer concentrations is a sensitive test in clinical practice to diagnose thrombotic states, including pulmonary embolism and Disseminated Intravascular Coagulation (DIC). 6 Increased D-dimer values have often been found in COVID-19 patients and were higher in the cases who are critically ill or those who die. [7] [8] [9] [10] [11] [12] [13] The aimof our study was to find out the prevelance of elevated D-dimer levels in confirmed COVID-19 Thus, the calculated sample size was 79. During that period a total of 138 patients were admitted in the COVID-ICU out of which 95 fulfilled the study inclusion criteria. Hence, samples from 95 patients were included. The patient aged more than 16 years with positive real-time polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 and requiring ICU management were included after obtaining a written consent. GPP-100 Specific Protein Analyzer for quantitative determination of D-dimer in human plasma was used for the D-dimer testing. The principle applied is Immunonephelometry. This method measures the light scattered by the insoluble immune complexes formed between D-dimer in the sample and its specific antibodies, and the amount of light scattered is directly proportional to the concentration of D-dimer when the antiserum is in excess. Reference range (less than 0.35 mg/L) was considered as normal D-dimer and D-dimer greater than 0.35 mg/L was considered as elevated D-dimer according to UCMS laboratory range. D-dimer values were collected at two time points: at the admission, and highest value during hospital stay.

Data were entered and analyzed in Statistical Package for the Social Sciences version 25.0 (SPSS). Descriptive statistics like frequency, percentage, mean and standard deviation were obtained.

Out of total 95 cases of COVID-19 included in this study, 25 (89.3%) patients with age ≥65 years and 42 (62.69%) patients aged <65 years had elevated D-dimer on admission. Out of total 59 (62.1%) male, Fourty four (74.6%) male and out of total 36 (31.9%) female, 23 (63%) female had elevated D-Dimer.

The mean age was 56.2±14.9 ranging from 16 years to 90 years. Shortness of breath 78 (82.1%), fever 67 (70.5%), and cough 60 (63.1%) were among the leading presenting complains in our study population. In addition, 12 (12.6%) had anosmia, 16 (16.8%) had diarrhea, and 14 (14.7%) had headache. Among the comorbidities, Hypertension was present in 32 (33.7%), Diabetes mellitus was present in 23 (24.2%), Chronic Obstructive Pulmonary Disease (COPD) in 3 (3.1%), Chronic Kidney Disease (CKD) in 3 (3.1%), and Bronchial Asthma was seen in 1 (1.01%). Out of the total 95 patients, mortality was observed in 43 (45.3%). The mean number of days of ICU stay was 8.2±4.2 days (Table 1) . 

In our study, we have identified elevated D-dimer level in significant number of the cases of RT-PCR positive COVID-19 patients admitted to COVID ICU. The D-dimer is a relatively small protein fragment that is present in the blood following degradation of blood clots by fibrinolysis. The determination of circulating D-dimer concentrations is a sensitive test in clinical practice to diagnose thrombotic states, including pulmonary embolism and DIC. 6 Christensen et.al reported that increased D-dimer values has often been found in COVID-19 patients. 7 This was also shown in our study where 87.36% of the total cases had elevated D-dimer levels at any time during their hospital stay.

In our study, elevated D-dimer levels was found to be higher in age group >65 years, 28 (100.0%) out of which 25 patients had elevated levels during admission. Also, 29 (67.4%) patients having elevated D-dimer at admission had mortality. All the 43 patients who died had elevated D-dimer levels during their hospital stay. These findings were comparable with study done by Mamta etal. 15 In patients with confirmed COVID-19, D-dimer has been reported to be higher in cases who are critically ill or those who die. [7] [8] [9] [10] [11] [12] [13] This finding is comparable to our study where all the cases with mortality had elevated D-dimer levels. In a study conducted by Zhang et al. there were 13 deaths during hospital stay out of which 12 were among patients whose D-dimer levels more than 2.0 mg/L. 16 17 Since diabetes is a prothrombotic state patients with diabetes have increased risk of thromboembolic events due to imbalance between clotting factor and firbrinolysis. 18

This study cannot be generalized as it is a single centered study and only in hospital mortality were included in the study. Further assessment of the discharged patients and their D-dimer levels were not done. A larger sample and multicenter study are needed to address these issues.

Elevated D-dimer levels was frequently seen in patients admitted in Intensive Care Unit with COVID-19. In patients with confirmed COVID-19, coagulopathy was found to be a major complication and was closely related to the disease severity and mortality. All patients who died had elevated D-dimer levels anytime during their hospital stay. Our study suggested that measurement of D-dimer can guide in clinical decision making.

COVID-19 and coagulopathy

COVID-19 and venous thromboembolism: a meta-analysis of literature studies

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19

A proposal for staging COVID-19 coagulopathy

D-dimer:anoverview of hemostasis and fibrinolysis, assays, clinical applications

Hematology laboratory abnormalities in patients with coronavirus disease 2019 (COVID-19)

Coagulation abnormalities and thrombosis in patients with COVID-19

Elevated D-Dimer evels are associated with increased risk of mortality in COVID-19: A systematic review and meta-analysis

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

D-dimer is associated with severity of coronavirus disease 2019: A pooled analysis

Interim Intensive Care Unit (ICU) Protocol for the care of patients with COVID-19 by Nepalese Society of Critical Care Medicine

D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases, diabetes & metabolic syndrome

D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19

Anchit Raj Singh. Relation of D-dimer levels of COVID-19 patients with diabetes mellitus